scout

Sandy Srinivas, MBBS, Stanford Cancer Center

Articles by Sandy Srinivas, MBBS, Stanford Cancer Center

Frontline Metastatic RCC: Pembrolizumab Plus Axitinib

ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center

Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.

Frontline Metastatic RCC: Nivolumab Plus Ipilimumab

ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center

Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.